Lung-Yi Mak

2 months ago | onlinelibrary.wiley.com | Karen Ho |Lung-Yi Mak

The recent re-naming and reclassification of ‘non-alcoholc fatty liver disease (NAFLD)’ to steatotic liver disease (SLD) subcategories aims to clarify the different aetiologies associated with liver fat accumulation, particularly alcohol consumption and/or metabolic dysfunction [1].

Aug 15, 2024 | nature.com | Lung-Yi Mak |Ken Liu |Sakkarin Chirapongsathorn |Nobuharu Tamaki |Mara Teresa Panlilio |Rashid Lui | +5 more

AbstractGlobally, nearly half of deaths from cirrhosis and chronic liver diseases (CLD) and three-quarters of deaths from hepatocellular carcinoma (HCC) occur in the Asia-Pacific region. Chronic hepatitis B is responsible for the vast majority of liver-related deaths in the region. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common form of CLD, affecting an estimated 30% of the adult population.

Jul 22, 2024 | onlinelibrary.wiley.com | Karen Ho |Lung-Yi Mak

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging public health issue with a global prevalence of 30%–40%.1 Resmetirom, a liver-directed thyroid hormone receptor-β agonist, is a newly FDA-approved drug in treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis based on its efficacy in achieving hepatic histological endpoints.2 With the approval of the first MASH-targeted therapy, other agents that were previously...

Jul 22, 2024 | onlinelibrary.wiley.com | Karen Ho |Lung-Yi Mak

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging public health issue with a global prevalence of 30%–40%.1 Resmetirom, a liver-directed thyroid hormone receptor-β agonist, is a newly FDA-approved drug in treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis based on its efficacy in achieving hepatic histological endpoints.2 With the approval of the first MASH-targeted therapy, other agents that were previously...

Jun 17, 2024 | thelancet.com | Lung-Yi Mak

The registration trials of tenofovir alafenamide in the population with chronic hepatitis B were published 8 years ago.Compared with tenofovir disoproxil fumarate, tenofovir alafenamide offers similar efficacy in terms of viral suppression and fewer bone and renal adverse events, and is therefore now recommended as a first-line oral antiviral for chronic hepatitis B.